Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board [Yahoo! Finance]
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board